News

Universal Display (OLED) delivered earnings and revenue surprises of +1.92% and -3.93%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Novanta (NOVT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Expensive stocks often command premium valuations because the market thinks their business models are exceptional. However, the downside is that high expectations are already baked into their prices, leaving little room for error if they stumble even slightly.

The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed down -0.26%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.17%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -1.12%. June E-mini S&P futures (ESM26 ) fell -0.36%, and June E-mini Nasdaq futures...

The S&P 500 Index ($SPX ) (SPY ) today is down -0.28%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.19%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.80%. June E-mini S&P futures (ESM26 ) are down -0.25%, and June E-mini Nasdaq futures...

The S&P 500 Index ($SPX ) (SPY ) today is up +0.93%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.89%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.17%. June E-mini S&P futures (ESM26 ) are up +0.76%, and June E-mini Nasdaq futures...

Healthcare stocks were rising pre-bell Tuesday, with the State Street Health Care Select Sector SPDR

A number of stocks jumped in the morning session after the industrial sector recovered, carried by the broad market rebound and a read-through from AI-driven capital expenditure commitments.

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a high-risk, high-reward environment due to the lack of reliable analyst price targets.

Understanding Novanta after its recent share move Novanta (NOVT) has drawn investor attention after a recent share price move, prompting a closer look at how the company’s current fundamentals line up with its recent market performance. See our latest analysis for Novanta. Novanta’s recent share price move comes after a strong run, with a 30 day share price return of 24.6% and a year to date share price return of 43.36%. The 1 year total shareholder return is 28.68%, but the 3 year total...

A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.

A number of stocks jumped in the afternoon session after the Dow hit a fresh all-time high above 50,700 as yields cooled off. Industrials are the most direct play on physical economic activity.

Novanta (NOVT) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Novanta’s first quarter saw a strong positive market reaction, reflecting confidence in management’s execution and commercial momentum. The company credited broad-based demand and robust bookings, particularly in the Robotics & Automation and Advanced Surgery businesses, as central to its performance. CEO Matthijs Glastra highlighted that every segment achieved double-digit bookings growth, with new product revenue rising sharply. Management specifically pointed to ongoing strength in medical co

Medicine and manufacturing technology provider Novanta (NASDAQ:NOVT) beat Wall Street’s revenue expectations in Q1 CY2026, with sales up 10.4% year on year to $257.7 million. Guidance for next quarter’s revenue was better than expected at $261.5 million at the midpoint, 1.4% above analysts’ estimates. Its non-GAAP profit of $0.81 per share was 4.3% above analysts’ consensus estimates.

Companies In The News Are: SPG, HIMS, NOVT, HALO.

Medicine and manufacturing technology provider Novanta (NASDAQ:NOVT) will be announcing earnings results this Monday after market close. Here’s what to expect.

This is Ray Nash, Corporate Finance Leader for Novanta. With me on today's call is our Chair and Chief Executive Officer, Matthijs Glastra; and our Chief Financial Officer, Robert Buckley. Before we begin, we need to remind everyone of the safe harbor for forward-looking statements that we've outlined in our earnings press release issued last night and also those in our SEC filings.

Novanta Inc (NOVT) reports impressive revenue and bookings growth, driven by AI and robotics, while navigating cost pressures and geopolitical uncertainties.

Novanta (NASDAQ:NOVT) reported stronger-than-expected first-quarter 2026 results, with management citing broad-based bookings growth, accelerating demand in automation and medical markets, and rising exposure to artificial intelligence-related infrastructure applications. Chair and Chief Executive

Moby summary of Novanta Inc.'s Q1 2026 earnings call

Novanta (NOVT) delivered earnings and revenue surprises of +3.85% and +1.70%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Medicine and manufacturing technology provider Novanta (NASDAQ:NOVT) announced better-than-expected revenue in Q1 CY2026, with sales up 10.4% year on year to $257.7 million. Guidance for next quarter’s revenue was better than expected at $261.5 million at the midpoint, 1.7% above analysts’ estimates. Its non-GAAP profit of $0.81 per share was 4.3% above analysts’ consensus estimates.

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.

Expensive stocks often command premium valuations because the market thinks their business models are exceptional. However, the downside is that high expectations are already baked into their prices, leaving little room for error if they stumble even slightly.